Banner
Diversity Libraries Zelinsky Institute
Bioscreening Company Directory

Zelinsky Institute
Zelinsky Institute POB 8941
19711 Newark
DE United States
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website
Zelinsky Institute of Organic Chemistry is well-known throughout the world for prominent scientists, who have been working in the Institute. Among them are Academicians A. E. Favorsky, N. D. Zelinsky, A. A. Balandin, B. A. Kazansky, A. N. Nesmeyanov, I. N. Nazarov, I. L. Knunyants, A. E. Porai-Koshits, V. V. Korshak, L. F. Vereshchagin, M. M. Shemyakin, M. I. Kabachnik and many others.
Scientific Prizes named after Academicians N. D. Zelinsky and A. A. Balandin were founded by the Academy of Sciences to award outstanding investigations in the fields of organic chemistry, petrochemistry and organic catalysis.

Today the Institute accumulates highly qualified scientists well known in the country and abroad. More than 600 researchers are employed in the Institute, of which five are Academicians and six Corresponding Members of the Academy of Sciences; their fruitful activities were awarded by Orders and Scientific Prizes. Among people now employed in the Institute there are 24 prize-winners of Lenin, State, Demidov, and several Nominal Prizes of the Academy of Sciences.

Leading scientists of the ZIOC are Members of foreign Academies and Scientific Societies, Scientific Councils of Russian Academy of Sciences, Ministries and Departments, work actively in Editorial Boards of Russian and International journals, etc. During past years, research fellows of the Institute have published thousands of scientific papers and lectures, 125 monographs and collections of papers, more than 10 textbooks and methodic guides, many of which were published in several editions and translated into foreign languages; they are also authors of hundreds of inventions.

Several fundamental achievements were made at the Institute. A new physical phenomenon, resonance Raman scattering of light, was discovered; substantial contribution to the problem of double bonding at silicon and germanium atoms was made. Methods of study of structure and reactivity of organic compounds under ordinary and extreme conditions were developed and are successfully used. These include reactions at superhigh pressures, low-temperature stabilization and study of unstable species (carbenes, free radicals) in inert matrices, methods of phase-transfer catalysis, electrochemical processes. Universally recognized are advances of the Institute in such fields as chemistry of unsaturated compounds, carbenes, small cycles, nitro compounds, diazo compounds, heterocycles (especially comprising nitrogen and sulfur), organoboranes, and research of homolytic reactions.

Extensive studies of the structure of microbial and virus carbohydrate-containing biopolymers that were accomplished at ZIOC have led for the first time to the synthesis of artificial antigens comprising complex oligo- and polysaccharides, thus opening a fundamentally new approach for the preparation of vaccines and sera. Original research on steroid synthesis resulted in development of the first home-produced hormone preparations with separated biological functions.

Fundamental studies in the field of theory of organic catalysis were performed at the Institute. Also studied were elementary acts of several catalytic reactions, structure and physics of the catalyst surface (quantum chemistry approaches and modern instrumental methods were used in combination). Priority studies in such areas as catalytic transformations of hydrocarbons, syntheses using carbon monoxide and other one-carbon molecules, synthesis of bulk and fine chemicals, as well as asymmetric catalysis, were accomplished. Scientific principles for the preparation of new zeolite catalysts were formulated. Kinetic, physical and mathematical models of industrial processes and devices were designed.

Many developments of the Institute are implemented in industry of basic organic synthesis, oil-refining industry, pharmaceutical industry, and industry of plant protection agents. Collaboration of scientists of the Institute with the Special Design Bureau of the ZIOC that existed for 35 years played a great role in the development of scientific instrumentation in our country, especially in desing and manufacture of chromatographs.

During recent years, mathematical chemistry and computer synthesis have been successfully developed. Modern information technologies are now widely used at the Institute. The Institute is a host for international centers of networks EARN/BITNET, FREEnet, and National United Networks Coordination Center. The Institute also accommodates Moscow Information Center of the RAS — STN International, NMR Research Center of the RAS, Higher Chemical College of the RAS, and Scientific and Education Center of ZIOC and Moscow Chemical Lyceum.

Editorial offices of several leading Russian chemical journals ("Russian Chemical Bulletin", "Russian Chemical Reviews", "Kinetics and Catalysis", and "Mendeleev Communications" published jointly with the Royal Society of Chemistry, Great Britain) reside at the Institute; many researchers of the Institute are involved in their work.

The Institute traditionally organizes conferences on carbene chemistry, syntheses using one-carbon molecules, heterocyclic chemistry, catalysis and mechanisms of catalytic reactions, as well as scientific school on organic synthesis.
WaySearch
  
Powered by Sigsiu.NET RSS Feeds
Natural compounds derived from plants could yield hundreds of new drugs
Ancient Chinese cures translate into modern Western medicines
XXI Century Database of Traditional Chinese Medicine Released
Gene therapy and stem cells unite
Gene therapy shows promise in reducing HIV
7TH DUESSELDORF SYMPOSIUM ON IMMUNOTOXICOLOGY Biology of the Arylhydrocarbon Receptor
NYBG scientist says the plant world has "great potential" as a source of new medicines There are probably at least 500 medically useful chemicals awaiting discovery in plant species whose chemical constituents have not yet been evaluated for their potential to cure or treat disease, according to a new analysis by a New York Botanical Garden scientist who has more than 15 years of experience in collecting plants for natural-products discovery programs. Currently, 135 drugs on the market are derived directly from plants; the analysis indicates that at least three times as many disease-fighting substances have yet to be found that could be developed into drugs or used as the basis for further drug research. "Clearly, plant diversity has not been exhausted, and there is still great potential in the plant world," said James S. Miller, Ph.D., Dean and Vice President for Science at the Botanical Garden. Dr. Miller's analysis, "The Discovery of Medicines from Plants: A Current Biological Perspective," is published in the December issue of the peer-reviewed journal Economic Botany. To arrive at his estimate, Dr. Miller used a formula based on the ratio of the number of drugs that have been developed from plants to the number of plants that were screened to find those drugs. He then applied that ratio to the number of plant species that have not yet been screened. Because of uncertainties in some of those numbers, the formula yields a range of potential drug discoveries. While there is no general agreement among botanists about the number of plant species that are likely to exist, Dr. Miller concluded that there are 300,000 to 350,000 species of plants. Of those, he determined that the chemistry of only 2,000 species has been thoroughly studied, and perhaps only 60,000 species have been evaluated even partially for medicinally useful chemicals. Working with those numbers, Dr. Miller calculated that there are likely to be a minimum of 540 to 653 new drugs waiting to be discovered from plants; the actual number could be much greater. "These calculations indicate that there is significant value in continuing to screen plants for the discovery of novel bioactive medicinally useful compounds," concludes Dr. Miller, who has run natural-products discovery programs that have collected specimens in North America, Central and Southeast Asia, and Africa for government agencies, pharmaceutical companies, and academic programs. As part of his Economic Botany paper, Dr. Miller reviews the disappointing history of past plant-screening efforts and evaluates the potential for future programs. Technological advances in the 1970s and 1980s gave medical researchers the capacity to evaluate large numbers of plant samples. That prompted the federal government and large pharmaceutical companies to institute aggressive plant collecting and screening programs. Those programs led to the development of several important drugs such as Taxol from Taxus brevifolia (used in cancer treatment) and Camptothecin from Camptotheca acuminata (derivatives of which are used to treat cancer). Other drugs indirectly trace their discovery to natural-products research, including the anti-viral Oseltamivir, which derives from Illicium anisatum and is marketed in the United States as Tamiflu. The number of drug discoveries, however, was substantially less than anticipated. By the early 2000s, many of the large pharmaceutical companies had abandoned their efforts. Dr. Miller argues that one possible explanation for the low yield is the relatively crude way in which plant extracts were tested for their pharmaceutical potential. Plants may contain as many as 500 to 800 different chemical compounds, but the screening programs of the late 20th century used extracts made from a whole plant or at best extracts that contained many hundreds of compounds. Under those circumstances, one compound may interfere with the action of another, or the amount of one compound may be too small to register in a mix of hundreds of chemicals. To correct this problem, new technologies now allow researchers to separate complex mixtures of natural products into a "library" of relatively pure compounds that can be tested individually. A 2002 study demonstrated that testing such libraries dramatically improves discovery rates. Bringing these advances together with refinements in collecting strategies could lead to what Dr. Miller calls a "second renaissance" of natural-products discovery. Miller undertook his analysis to highlight the fact that despite past collecting programs, the plant world represents a poorly explored source of potentially lifesaving drugs. That adds urgency, he said, to efforts to conserve natural habitats so that species are not driven to extinction before they can be studied. "The natural world has a great and diverse array of interesting chemicals that have been only minimally studied and still hold considerable potential," he writes.Contact: Stevenson Swanson
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
718-817-8512
The New York Botanical GardenSource: http://www.eurekalert.org/pub_releases/2011-12/tnyb-nmc121211.phpLinks related to natural compounds and plant extracts:Natural Compounds
Plant Extracts
Natural and Natural Derivatives Libraries
 Read the Full Story
November 22, 2011 The Chem-TCM is the most comprehensive database of its kind and translates more than 12,000 chemicals from more than 300 Chinese herbs used in traditional Chinese medicine (TCM) into Western terminology. "Future researchers will now be able to better understand the chemical basis of remedies that have been in use for thousands of years," says David Barlow of King's College London (KCL), who has helped to develop the database. TCM chemicals are rarely used as raw materials to develop Western drugs because their complex nature makes the registration process difficult. The database may also answer one of TCM's regulatory challenges in the United Kingdom. An EU directive came into effect in the UK this May that makes it illegal for individual practitioners to sell TCM over the counter, except for varieties registered with the UK drug safety watchdog, the Medicines and Healthcare Products Agency. read more...
 Read the Full Story
  October 18, 2011 A comprehensive database developed by King’s College London researchers that features the chemical components found in traditional Chinese medicines has been released to market this month, allowing researchers to explore age-old remedies in the search for tomorrow’s new drugs. Read the Full Story
Two of the holy grails of medicine - stem cell technology and precision gene therapy - have been united for the first time in humans, say scientists. It means patients with a genetic disease could, one day, be treated with their own cells. Read the Full Story
(Reuters) - An early stage trial of Sangamo BioSciences Inc's HIV treatment found that the gene therapy reduced levels of the virus and even eliminated it in one patient with a naturally occurring gene mutation. Read the Full Story
Heinrich Heine University Duesseldorf
September 21 – 24, 2011 AhR research has taken great momentum recently, with a number of seminal discoveries, especially regarding its role in physiological events. This has opened new arenas, attracted new groups into the field, and led to a steep interest in the potential of AhR as a therapeutic target for the immune system, cancer and other diseases. We invite you to join us for this exciting meeting on the biology of AhR. Presentations by international renowned speakers. Read the Full Story
image Natural compounds derived from plants could yield hundreds of new drugs
image Ancient Chinese cures translate into modern Western medicines
image XXI Century Database of Traditional Chinese Medicine Released
image Gene therapy and stem cells unite
image Gene therapy shows promise in reducing HIV
image 7TH DUESSELDORF SYMPOSIUM ON IMMUNOTOXICOLOGY Biology of the Arylhydrocarbon Receptor

BioScreening News

  • Natural compounds derived from plants could yield hundreds of new drugs
    NYBG scientist says the plant world has “great potential” as a source of new medicines There are probably at least 500 medically useful chemicals awaiting discovery in plant species whose chemical constituents have not yet been evaluated for their potential to cure or treat disease, according to a new analysis...
  • Four anti-cancer compounds identified
    Sydney: Four new anti-cancer compounds have shown promise in inhibiting the growth of tumours, according to a new approach. Jason Smith, doing his M.Phil. in biomolecular sciences from Macquarie University, combined existing knowledge of an enzyme with computational chemistry approach to identify novel (cancer) inhibitors. The enzyme (indoleamine 2,3-dioxygenase) has...
  • Nigeria: FG and Cost of Cancer Screening
    THE Federal Government’s recent directive to its hospitals to reduce the cost of cancer screening, though very commendable, is long overdue, considering that late diagnosis of the disease has resulted in the high rate of cancer related deaths in the country. Cancer is one of the leading causes of deaths...
  • NMR Fine-Tuned for High-Content Metabolomics Screening
    Scientists report on the development of a nuclear magnetic resonance (NMR)-based method forscreening the metabolomic response of drug-treated mammalian cells to drug therapy. TheSanford-Burnham Medical Research Institute, and Rady Children’s Hospital investigators, say the highly sensitive, fast, and simple method is carried out in 96-well format, and could have particular utility...
  • Research at A&M and Scripps finds HIV-killing compound
    COLLEGE STATION - A powerful topical preventative for HIV, the virus that causes AIDS, could be a step closer to clinical trials, thanks to a newly discovered molecular compound that research at Texas A&M University and the Scripps Research Institute shows dissolves the virus on contact. The ability of the synthetic...
  • Ancient Chinese cures translate into modern Western medicines
    The Chem-TCM is the most comprehensive database of its kind and translates more than 12,000 chemicals from more than 300 Chinese herbs used in traditional Chinese medicine (TCM) into Western terminology. “Future researchers will now be able to better understand the chemical basis of remedies that have been in use...
  • First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results
    Initial data from the first ever trial to evaluate autologous cardiac stem cell (CSC) transplants in humans suggests that the treatment improves left ventricular (LV) systolic function by an average of 12% over one year, and reduces infarct size in patients with severe heart failure due to ischemic heart disease. The trial investigators say...
  • FDA Clears Abbott’s Confirmatory Chagas Disease Assay
    FDA approved Abbott’s in vitro enzyme strip assay for Chagas disease. The Abbott ESA Chagastest detects antibodies to the causative pathogen Trypanosoma cruzi in serum or plasma samples. It is indicated for use as an additional, more specific test on human samples that have been found to be repeatedly reactive using a licensed screening test. The T. cruzi parasite...
  • Chemie Uzbekistan 2011
    The 5th Anniversary Central Asian International exhibition «Chemical industry – Chemie Uzbekistan» and the 2nd Uzbek International exhibition of plastics and rubber – «Plastex Uzbekistan 2011» will be held from the 16th till the 18th of November 2011, at the Pavilion 1 of OJSS «Uzexpocentre». “ITE UZBEKISTAN” is the organizer...
  • Vaccine for ovarian, breast cancer shows promise
    (CBS) A new vaccine that targets ovarian and breast cancer has shown promise in early studies, giving scientists hope they may be closer to stopping the deadly diseases. PICTURES: 25 breast cancer myths busted Known as PANVAC, the vaccine triggers the immune system to attack tumor cells. “With this vaccine,...

Life Science Events

January 2012 February 2012 March 2012
Su Mo Tu We Th Fr Sa
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29
Recent events
View full calendar
1 DOW 12,883.95
+5.75 (0.04%)    
2 S&P 1,349.96
+2.91 (0.22%)    
3 NASDAQ 2,915.86
+11.78 (0.41%)